INTRODUCTION
Overview of Antibody-Based Therapeutics: Present and Future Promise, I.S. Grewal
BIOLOGICS FOR AUTOIMMUNITY AND INFLAMMATION
Biologic Therapies for Multiple Sclerosis, P. Fontoura and H. Garren
Biologic Therapies in Rheumatoid Arthritis, M.J. Houseman and J.D. Isaacs
Biologic Therapies in Systemic Lupus Erythematosus, R. Eisenberg
Biologic Therapies for Inflammatory Bowel Disease, M.H. Holtmann and M.F. Neurath
Biologic Therapies for Psoriasis, R. Saraceno and S. Chimenti
TNFa Inhibitors: Emerging Biologic Therapies for the Treatment of Asthma, S. Natarajan, L.J. Vaickus, J. Kim, and D.G. Remick
Protein-Based Therapies in Experimental and Clinical Transplantation, G. Benichou, S. de Haseth, A.B. Cosimi, and A. Alessandrini
Biologic Therapies for Type 1 Diabetes, T.L. Van Belle and M.G. von Herrath
BIOLOGICS FOR HEMATOLOGICAL MALIGNANCIES
Biologic Therapies for Acute Myeloid Leukemia/Myelodysplastic Syndrome, J. Pinilla-Ibarz and C. Bello
Biologic Therapies for Non-Hodgkin Lymphoma and Hodgkin Disease, S.M. Ansell
Biologic Therapies for Chronic Lymphocytic Leukemia, M.A. Kharfan-Dabaja and E.S. Santos
Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders, S. Ozaki
DEVELOPMENT OF BIOTHERAPIES FOR SOLID TUMORS
Antibody-Based Therapies for Carcinomas, D. Schrama and J.C. Becker
Role of Vascular Targeting Agents in the Treatment of Solid Tumors: Current and Future Developments, H.-P. Gerber, I.S. Grewal, and E. Oflazoglu
Recent Advancements in the Use of Antibody–Drug Conjugates for Cancer Therapy, P.D. Senter and D.R. Benjamin
INDEX
Biography
Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.
